(Original title: Plate change | Heparin concept stocks rise as unexplained childhood hepatitis ravages the United States and Europe)
The Zhitong Finance APP was informed that on April 25, affected by the news of hundreds of children’s hepatitis cases of unknown origin reported in many countries, the A-share heparin concept stocks rose. 002550.SZ), Fosun Pharma (600196.SH), China Resources Shuanghe (600062.SH), Changshan Pharmaceutical (300255.SZ), Essence Pharma (002349.SZ) and other stocks rose.
The World Health Organization said on the 23rd local time that as cases of acute hepatitis of unknown origin increased among children, one child has been reported to die. According to statistics, a total of 12 countries have reported at least 169 cases of children, of which 114 occurred in the United Kingdom. As of April 21, countries reporting cases include the United States, Spain, Israel, Denmark, Ireland, the Netherlands, Italy, Norway, France, Romania and Belgium, in addition to the United Kingdom. On April 21, local time, the U.S. Centers for Disease Control and Prevention (CDC) issued a nationwide warning, requiring all physicians to pay attention and report all suspected cases of hepatitis of unknown origin to local health departments.
The agency pointed out that viral hepatitis is a major health challenge globally and in our country, killing millions of people every year. To eliminate the threat of viral hepatitis, at the 69th World Health Assembly, WHO’s 194 member states voted to adopt the “Global Health Sector Strategy on Viral Hepatitis”, committing to “eliminate the public health threat of viral hepatitis by 2030″ with specific goals By 2030, the number of new global hepatitis infections will be reduced by 90%; the number of deaths due to hepatitis virus infection and related diseases will be reduced by 65%; the rate of standardized antiviral treatment will be increased to 80%; level. In this context, hepatitis drugs will usher in a period of rapid development in the next few years. my country is the country with the heaviest burden of liver disease in the world, with 90 million hepatitis B virus (HBV) carriers, 10 million hepatitis C virus (HCV) carriers, 170-310 million nonalcoholic liver disease patients, and 7 million liver cirrhosis patients. . In view of the large unmet treatment needs of liver diseases, the market space for innovative drugs is worth looking forward to. There are many companies both at home and abroad in this field. It is recommended to pay attention to the leading companies of innovative drugs for liver diseases.